RedHill Biopharma Ltd. provided earnings guidance for fourth quarter of 2021. For the quarter, the company record Q4/2021 total net revenues estimated to be in the range of $22-24 million vs. $21.6 million in Q3/2021 and $21.5 in Q4/2020.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4319 USD | -6.43% | -5.72% | -70.42% |
Jun. 06 | RedHill Biopharma Ltd. Announces Resignation of Alla Felders as Member of the Board | CI |
May. 06 | Redhill Biopharma Awarded China Patent for Investigational Ebola Drug Opaganib | MT |
1st Jan change | Capi. | |
---|---|---|
-70.42% | 14.71M | |
+0.82% | 93.19B | |
-1.32% | 39.62B | |
-12.88% | 33.78B | |
+64.77% | 26.82B | |
-16.31% | 15.35B | |
-5.78% | 13.13B | |
-11.38% | 11.6B | |
-49.84% | 10.26B | |
+5.24% | 9.43B |
- Stock Market
- Equities
- RDHL Stock
- News RedHill Biopharma Ltd.
- Redhill Biopharma Ltd. Provides Earnings Guidance for Fourth Quarter of 2021